Q-omics provides the consensus-scored ANKRD45 profile across patient tissues and cancer cell-line models. ANKRD45 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD45 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANKRD45 RNA expression shows 16,404 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where ANKRD45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD45 survival associations across molecular data types. ANKRD45 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD45 RNA expression–survival associations across cancer types. High ANKRD45 expression shows unfavorable associations in LGG, but favorable associations in UVM, SKCM, LUAD, LUSC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD45 RNA expression.
This table summarizes ANKRD45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD45 shows lower tumor expression in KIRC, KICH, LUSC, BRCA and COAD and higher tumor expression in LIHC. The KIRC box plot shows higher ANKRD45 RNA expression in normal versus tumor tissue (log2 FC = −1.145, t-test p < 0.001).
This table shows molecular features associated with ANKRD45 in patient tissues and cancer cell lines. In patient samples, ANKRD45 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
